Lesch-Nyhan Syndrome
Overview
Plain-Language Overview
Lesch-Nyhan Syndrome is a rare genetic disorder that primarily affects the nervous system and metabolism. It is caused by a problem with an enzyme that helps the body recycle certain building blocks of DNA and RNA, leading to a buildup of uric acid. This excess uric acid can cause painful gout-like symptoms and kidney problems. The syndrome also causes severe neurological symptoms, including muscle stiffness, involuntary movements, and difficulty controlling movements. A hallmark feature is self-injurious behavior, such as biting lips and fingers. The condition usually appears in early childhood and affects mostly boys because it is linked to the X chromosome.
Clinical Definition
Lesch-Nyhan Syndrome is an X-linked recessive disorder caused by a deficiency of the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT), encoded by the HPRT1 gene. This enzyme deficiency leads to impaired purine salvage, resulting in excessive production and accumulation of uric acid. The disorder is characterized by a triad of hyperuricemia, neurodevelopmental delay, and self-mutilating behaviors. Neurologic manifestations include dystonia, choreoathetosis, and spasticity, often accompanied by intellectual disability. The overproduction of uric acid predisposes patients to gouty arthritis, nephrolithiasis, and renal failure. The syndrome is clinically significant due to its severe neurobehavioral phenotype and metabolic complications.
Inciting Event
There is no external trigger; the disease results from inherited HPRT1 gene mutations present at conception.
Symptom onset is related to enzyme deficiency manifesting as purine metabolism abnormalities after birth.
Latency Period
Symptoms usually appear within the first 3 to 6 months of life as neurological and behavioral abnormalities develop.
Hyperuricemia and gout manifestations may be delayed until later infancy or early childhood.
Diagnostic Delay
Early neurological symptoms are often misattributed to cerebral palsy or other neurodevelopmental disorders.
Lack of awareness of self-mutilation and hyperuricemia association delays diagnosis.
Failure to perform uric acid measurement and enzyme assay in suspected cases prolongs diagnostic delay.
Rarity of the disease and nonspecific early symptoms contribute to under-recognition.
Clinical Presentation
Signs & Symptoms
Neonatal hypotonia progressing to spasticity and dystonia in infancy.
Self-injurious behavior typically beginning between 1 and 3 years of age.
Developmental delay and intellectual disability of variable severity.
Gouty arthritis and nephrolithiasis secondary to chronic hyperuricemia.
Choreoathetosis and dystonia causing abnormal involuntary movements.
History of Present Illness
Progressive developmental delay and hypotonia begin in infancy.
Onset of self-injurious behaviors such as lip and finger biting typically occurs by 1 year of age.
Patients develop choreoathetosis, dystonia, and spasticity as neurological symptoms worsen.
Recurrent gouty arthritis and nephrolithiasis may present in early childhood.
Feeding difficulties and irritability are common early complaints.
Past Medical History
No prior illnesses are typically present before symptom onset as this is a congenital metabolic disorder.
History may include recurrent uric acid kidney stones or gout in early childhood.
No history of infections or trauma related to neurological symptoms.
Family History
Positive family history of affected males with similar neurological and behavioral symptoms is common.
Maternal relatives may be asymptomatic carriers of the HPRT1 mutation.
Family history of gout or kidney stones in male relatives may be present.
Physical Exam Findings
Self-mutilating behaviors such as lip and finger biting with resultant tissue injury.
Dystonia and choreoathetosis causing abnormal involuntary movements and posturing.
Spasticity and hyperreflexia indicating upper motor neuron involvement.
Gouty tophi or joint swelling due to hyperuricemia in older patients.
Growth retardation and microcephaly may be present in affected children.
Diagnostic Workup
Diagnostic Criteria
Diagnosis is established by demonstrating markedly reduced or absent activity of HGPRT enzyme in erythrocytes or fibroblasts. Elevated serum and urine uric acid levels support the diagnosis. Genetic testing confirming mutations in the HPRT1 gene provides definitive confirmation. Clinical features such as self-injurious behavior, dystonia, and developmental delay in a male patient further support the diagnosis. Brain imaging and other tests may be used to exclude alternative causes but are not diagnostic.
Pathophysiology
Key Mechanisms
Complete deficiency of the hypoxanthine-guanine phosphoribosyltransferase (HGPRT) enzyme due to mutations in the HPRT1 gene leads to impaired purine salvage.
Excessive degradation of purines results in hyperuricemia and increased uric acid production causing gout and nephrolithiasis.
Neurological dysfunction arises from dopaminergic neuron dysfunction in the basal ganglia, contributing to movement disorders and behavioral abnormalities.
Self-mutilation behaviors are linked to impaired neurotransmitter regulation and basal ganglia damage.
Accumulation of phosphoribosyl pyrophosphate (PRPP) stimulates de novo purine synthesis, exacerbating uric acid overproduction.
| Involvement | Details |
|---|---|
| Organs | Brain dysfunction, especially in the basal ganglia, causes neurological and behavioral symptoms. |
Kidneys are involved due to uric acid nephropathy and risk of renal failure. | |
| Tissues | Basal ganglia tissue is involved in the pathogenesis of dystonia and self-injurious behavior. |
Renal tissue is affected by uric acid crystal deposition causing nephropathy. | |
| Cells | Neurons in the basal ganglia are critically affected, leading to motor dysfunction and behavioral abnormalities. |
Erythrocytes show elevated levels of hypoxanthine-guanine phosphoribosyltransferase (HGPRT) deficiency markers. | |
| Chemical Mediators | Uric acid accumulation causes gout and nephrolithiasis in Lesch-Nyhan syndrome. |
Hypoxanthine-guanine phosphoribosyltransferase (HGPRT) deficiency leads to impaired purine salvage and excess uric acid production. |
Treatments
Pharmacological Treatments
Allopurinol
- Mechanism:
Inhibits xanthine oxidase to reduce uric acid production.
- Side effects:
Rash
Gastrointestinal upset
Hepatotoxicity
- Clinical role:
First-line
Benzodiazepines
- Mechanism:
Enhance GABAergic inhibition to reduce self-injurious behavior and spasticity.
- Side effects:
Sedation
Dependence
Cognitive impairment
- Clinical role:
Adjunctive
Allopurinol plus hydration
- Mechanism:
Prevents urate nephropathy by lowering serum uric acid and promoting renal clearance.
- Side effects:
Hypersensitivity reactions
Renal impairment
- Clinical role:
Long-term control
Non-pharmacological Treatments
Behavioral therapy and protective devices to prevent self-mutilation.
Physical therapy to manage spasticity and improve motor function.
Nutritional support to maintain adequate growth and prevent complications from feeding difficulties.
Prevention
Pharmacological Prevention
Allopurinol to reduce uric acid production and prevent gout and nephrolithiasis.
Benzodiazepines or baclofen to manage spasticity and dystonia symptoms.
Neuroleptics may be used cautiously to reduce self-injurious behavior.
Antiepileptic drugs if seizures are present.
Non-pharmacological Prevention
Behavioral therapy and protective restraints to minimize self-mutilation.
Regular dental care and oral hygiene to prevent infections from biting injuries.
Physical and occupational therapy to improve motor function and reduce spasticity.
Hydration and dietary modifications to reduce uric acid crystallization risk.
Outcome & Complications
Complications
Severe tissue damage from persistent self-mutilation leading to infections and deformities.
Chronic kidney disease from uric acid nephropathy.
Aspiration pneumonia due to impaired swallowing and neurological dysfunction.
Psychosocial impairment from behavioral and cognitive deficits.
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Lesch-Nyhan Syndrome versus Cerebral Palsy
Lesch-Nyhan Syndrome | Cerebral Palsy |
|---|---|
Symptoms typically appear after a few months of normal development | Motor symptoms present from birth or early infancy |
Progressive neurobehavioral deterioration with self-injurious behavior | Non-progressive motor impairment |
Markedly elevated serum and urine uric acid levels | Normal uric acid levels |
Lesch-Nyhan Syndrome versus Hunter Syndrome (Mucopolysaccharidosis II)
Lesch-Nyhan Syndrome | Hunter Syndrome (Mucopolysaccharidosis II) |
|---|---|
X-linked recessive inheritance | X-linked recessive inheritance |
Elevated uric acid in serum and urine | Elevated glycosaminoglycans in urine |
Self-mutilation, choreoathetosis, and spasticity without coarse facies | Coarse facial features, hepatosplenomegaly, and joint stiffness |
Lesch-Nyhan Syndrome versus Wilson Disease
Lesch-Nyhan Syndrome | Wilson Disease |
|---|---|
Symptoms usually begin in infancy or early childhood | Typically presents in adolescence or young adulthood |
Elevated serum and urine uric acid | Low serum ceruloplasmin and elevated hepatic copper |
Self-injurious behavior and neurological symptoms without liver disease | Kayser-Fleischer rings and hepatic dysfunction |
Lesch-Nyhan Syndrome versus Severe Combined Immunodeficiency (SCID)
Lesch-Nyhan Syndrome | Severe Combined Immunodeficiency (SCID) |
|---|---|
X-linked recessive inheritance | Various inheritance patterns including X-linked and autosomal recessive |
Normal lymphocyte counts with hyperuricemia | Profound lymphopenia and absent T-cell function |
Self-mutilation and neurological symptoms without immunodeficiency | Severe recurrent infections and failure to thrive |
Lesch-Nyhan Syndrome versus Rett Syndrome
Lesch-Nyhan Syndrome | Rett Syndrome |
|---|---|
X-linked recessive disorder affecting males | Almost exclusively affects females due to de novo mutations in MECP2 |
Symptoms appear in infancy with early developmental delay | Normal development for 6-18 months followed by regression |
Self-injurious behavior with dystonia and choreoathetosis | Loss of purposeful hand skills and stereotypic hand-wringing |